Debt Refinancing Aquestive Therapeutics recently completed a $150 million debt refinancing, indicating strong investor confidence and potential capacity for strategic investments in R&D, manufacturing scale-up, or to finance new delivery technology partnerships.

Litigation Activity There are multiple securities fraud lawsuits and investor class actions involving Aquestive, suggesting heightened due diligence for potential partners or clients regarding compliance narratives, financial disclosures, and risk management when engaging in collaborations.

Leadership Change Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer signals a governance and compliance emphasis; opportunity to align collaborations with a strengthened framework for contractual, licensing, and regulatory affairs.

Delivery Technologies As a pharmaceutical company focused on innovative medicine delivery, there is a clear cross-sell potential for formulation science, novel drug delivery platforms, and injectable or oral solubility technologies to partner with manufacturers seeking advanced therapies.

Scale and Markets With mid-tier revenue and a smaller employee base relative to peers, Aquestive may be seeking efficiency gains, contract manufacturing arrangements, or co-development deals to expand capacity and market reach without large in-house expansion.